Oxcarbazepine (All indications) updated on 04-22-2025

Extremely preterm (< 28 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9087
R31106		 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Gestational age at birth (22-26 WA) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 5.89 [0.82;42.16] C 1/143   2,041/1,710,441 2,042 143
ref
Total 1 studies 5.89 [0.82;42.16] 2,042 143
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020Coste, 2020 1 5.89[0.82; 42.16]2,0421430%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA0.920.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 5.89[0.82; 42.16]2,042143 -NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 5.89[0.82; 42.16]2,042143 -NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 1 Tags Adjustment   - No  - No 5.89[0.82; 42.16]2,042143 -NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 1 All studiesAll studies 5.89[0.82; 42.16]2,042143 -NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 10.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 5.89[0.82; 42.16]2,042143 -NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 10.510.01.0